【股票】讨论Sihuan四环制药0.975元被收购还有没有买入价值？

老鼠爱小米

Sihuan 四环制药

龙筹股，盘子470M，生产抗生素的，小时候没少吃过他家的药药。很印象的是小时候吃四霉素吃了牙齿黄。叫做四环素牙。

上个星期五，收盘在0.765元，成交量稀少。

星期一，发布公告，股票停盘。

星期二，开盘直接【跳空】高开了0.195至0.955元,差点多了2毛钱。
一整天在0.950~0.965之间做窄幅波动。收盘在0.955元。

走势图上形成了一个【跳空缺口】的【十字星】。

今天呢，买盘Q十分之大，6千多，卖盘1千多Q。可是成交的量却很少。那么多大单子的买卖Q（每价位都是几千Q），为何成交的量才几百手？
股价方面，平开0.955元，然后动也不动。卖价0.960都不能成交。

有个问题我很不明白：昨天的买卖单我晚上做功课时看到，基本全部是卖，为什么股价不跌反涨？

四环这只股票现在的情形，让我想起了中国石油收购SPC的那天的事情，好像是一致的。SPC的被收购价是6。25元，当天直接跳到6。20元，然后就在这个价位周围做【窄幅波动】，不跌也不涨。可是SPC每天的买卖Q都是几千单，却成交不到。


*DJ China Pharma Made S$0.975/Shr Offer For Sihuan Pharm Hldgs
(MORE TO FOLLOW) Dow Jones Newswires
August 24, 2009 19:57 ET (23:57 GMT)
Copyright (c) 2009 Dow Jones & Company, Inc.

DJ MARKET TALK: Sihuan Pharma Likely Up On Takeover Bid Premium
2357 GMT [Dow Jones] Sihuan Pharmaceutical (BL5.SG) likely to gap up when trading resumes at market open as offer from privately-held China Pharma to take over drug maker at premium to stock's average price over past 12 months. Bermuda-incorporated China Pharma, together with concerted parties including Sihuan's key management team, will offer S$0.975/share for rest of Sihuan it doesn't already own, valuing company at S$458.3 million vs current S$359.6 million market cap. Offer represents 27.5% premium over last closing price, 24.4%-46.4% premium over average price for past 1-12 months, almost 3X its book value. Buyer plans to delist Sihuan, citing low trading liquidity. Adds, taking company private will give management flexibility to manage business amid uncertain operating environment. Major shareholders, representing 76.2% of Sihuan, have agreed to accept offer. Stock halted yesterday, last closed at S$0.765. (FKH)
Contact us in Singapore. 65 64154 150; [email protected] DJ MARKET TALK: Sihuan +24.2%; Delisting May Be Ideal -Analyst
0214 GMT [Dow Jones] Sihuan Pharmaceutical (BL5.SG) gaps up at opening, last +24.2% at S$0.95 on above-average volume, as stock closes in on S$0.975/share takeover price from China Pharma. Given stock's thin trading liquidity, tough operating climate, foreign house analyst says delisting Sihuan may be ideal option; "the industry (in China) has always been quite fragmented, with many players around. A privatized company would be in a better operating position as it wouldn't have to spend money on fees related to its listing status, while being freed from seeking shareholders' approval for any growth plans." Adds, longer-term prospects for companies like Sihuan remain positive; "their drugs are not sold over the counter, but are available only on prescription. The government wants to reach out to the rural areas, which do not have much access to prescription drugs. So growth, in that sense, is still there." Offer represents 27.5% premium over last closing price, almost 3X its book value. Resistance expected at offer price. (FKH)

老鼠爱小米

买价955，卖价955，960都卖不出。

Q一大堆，股价不动。


典型的被操纵股。